City of Hope

University of Southern California

Los Alamos National Security, LLC

Beckman Research Institute of City of Hope

John E Shively

Jerome M Bailey

Anna M Wu

Andrew A Raubitschek

Mark A Sherman

Lin Li

David A Horne

Jun Xie

Arthur D Riggs

Piotr Marek Swiderski

Paul J Yazaki

Tove Olafsen

Junfeng Li

Zijie Sun

Zhifang Zhang

Michael Neumaier

Hua Yu

Basil I Swanson

Peter Conti

Andreas Herrmann

Jennifer Suzanne Martinez

Zibo Li

Miro Rusnak

Zhanhong Wu

Shuanlong Liu

Jimmy R Calaycay

Narmada R Shenoy

Kenneth S Graham

Y H Yang

Charles W Todd

Frances G Crawford

Maciej Kujawski

The compositions and methods provide herein include, inter alia, antibodies attached to single-stranded oligoribonucleotides. Two antibodies are capable of forming complexes in vivo through hybridization of the respective complementary oligoribonucleotides they are bound to. For example, a first antibody bound to a first oligoribonucleotide through a first chemical linker may be administered to a subject, bind to a cell surface antigen in vivo and subsequently form an antibody complex in vivo with a second antibody bound to a second oligoribonucleotide through a second chemical linker, through complementary base-pairing between the first and the second oligoribonucleotide. The compositions and methods provided herein are, inter alia, useful for diagnostic and therapeutic purposes, for example, the treatment of cancer or autoimmune disease.

Complementary RNA linked bispecific T-cell engaging antibodies

Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Methods of treating advanced prostate cancer

Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.

Cell penetrating conjugates and methods of use thereof

A thio-selective radioactive labeling agent has the following general formula:*R-L-VS,

Vinylsulfone-based 18F-labeling compositions and methods and uses thereof

The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.

Covalent disulfide-linked diabodies and uses thereof

In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils.

Generation of novel bone forming cells (monoosteophils) from LL-37 treated monocytes

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

Humanized anti-CEA T84.66 antibody and uses thereof

An assay element is described including recognition ligands adapted for binding to carcinoembryonic antigen (CEA) bound to a film on a single mode planar optical waveguide, the film from the group of a membrane, a polymerized bilayer membrane, and a self-assembled monolayer containing polyethylene glycol or polypropylene glycol groups therein and an assay process for detecting the presence of CEA is described including injecting a possible CEA-containing sample into a sensor cell including the assay element, maintaining the sample within the sensor cell for time sufficient for binding to occur between CEA present within the sample and the recognition ligands, injecting a solution including a reporter ligand into the sensor cell; and, interrogating the sample within the sensor cell with excitation light from the waveguide, the excitation light provided by an evanescent field of the single mode penetrating into the biological target-containing sample to a distance of less than about 200 nanometers from the waveguide thereby exciting any bound reporter ligand within a distance of less than about 200 nanometers from the waveguide and resulting in a detectable signal.

Planar optical waveguide based sandwich assay sensors and processes for the detection of biological targets including early detection of cancers

C-terminal sequencing of peptides which may include proline

A method for C-Terminal degradation of peptides and proteins involves forming a thiohydantoin derivative of the C-Terminal amino acid and then cleaving the derivatized amino acid by reaction with methoxide or methiolate ions.

Method for C-terminal degradation of peptides and proteins

A method and apparatus for sequencing polypeptides, including a continuous flow reactor which may include a sample bearing membrane strip.

Protein or peptide sequencing method and apparatus

Growing community of inventors

Arcadia, CA, United States of America

John E Shively